What Has Driven the Growth of the Liver Disease Diagnostics Market in Recent Years?
The liver disease diagnostics market has seen considerable growth due to a variety of factors.
• In the past few years, the market for liver disease diagnostics has seen significant growth. The market, valued at $36.26 billion in 2024, is projected to escalate to $39.05 billion in 2025, with a compound annual growth rate (CAGR) of 7.7%.
Factors contributing to this growth during the historic duration include the rising occurrences of acute and chronic liver diseases, increased alcohol consumption, heightened health consciousness about liver health, and the development of healthcare infrastructures.
What Is The Projected Growth And Market Size For The Liver Disease Diagnostics
The liver disease diagnostics market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations are high for the liver disease diagnostics market to experience significant expansion in the coming years. The market is projected to reach $52.04 billion in 2029, with a compound annual growth rate (CAGR) of 7.4%.
This growth throughout the forecast period is associated with factors such as an aging population, increased spending on research and development, a rise in the number of biopsy procedures and disease cases, and broader acceptance of telemedicine. Key market trends within this period involve the emergence of personalized medicine, technological innovation in diagnostic kit manufacturing, progress in rapid testing, technological enhancement in the healthcare industry, and advancements in diagnostic techniques.
What Factors Are Driving Growth In The Liver Disease Diagnostics Market?
The surge in alcohol intake is anticipated to accelerate the progress of the liver disease diagnostics market in the future. Factors such as changes in social standards, improved affordability, increased accessibility, and heightened stress or mental health issues are causing an escalation in alcohol consumption. Liver disease diagnostics play a vital role in evaluating the effects of alcohol consumption on liver health, aiding in the identification of early indications of liver deterioration such as fatty liver, hepatitis, or cirrhosis. As an illustration, data from the National Health Service, a government department in England, revealed in December 2022 that the proportion of people who had alcohol over the past 12 months escalated with age, beginning at 62% for those between 16 to 24, leading up to 85% for those between 55 to 74 years. Consequently, the upsurge in alcohol consumption is fueling the growth of the liver disease diagnostics market.
What Are The Main Segments Of The Global Liver Disease Diagnostics Market?
The liver disease diagnostics market covered in this report is segmented –
1) By Diagnosis Technique: Laboratory Tests, Imaging, Endoscopy, Biopsy, Other Diagnosis Techniques
2) By Disease: Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, Fibrosis, Cirrhosis, Hepatocellular Carcinoma, Other Diseases
3) By End Users: Hospitals, Laboratories, Other End Users
Subsegments:
1) By Laboratory Tests: Blood Tests (Liver Function Tests, Hepatitis Panel), Enzyme Tests (ALT, AST, ALP), Genetic Testing, Serological Tests
2) By Imaging: Ultrasound Imaging, CT Scans, MRI, Elastography (FibroScan)
3) By Endoscopy: Esophagogastroduodenoscopy (EGD), Capsule Endoscopy
4) By Biopsy: Liver Biopsy (Needle Biopsy), Fine Needle Aspiration Biopsy, Laparoscopic Biopsy
5) By Other Diagnosis Techniques: Molecular Imaging, Biomarker Testing, Fibrosis Scoring Systems
Pre-Book The Liver Disease Diagnostics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Liver Disease Diagnostics Market Landscape?
Key players in the liver disease diagnostics market are concentrating on the creation of innovative solutions, like non-invasive instruments for liver evaluation, in an effort to develop more precise and effective diagnostic methods. Non-invasive methods for liver evaluation refer to those which examine liver health using methods such as elastography or blood tests, thus avoiding invasive procedures like biopsies. For instance, City Imaging & Clinical, a diagnostics center based in India, in September 2024, introduced FibroScan, a non-invasive tool for evaluating liver health. It is intended for early identification of liver conditions like non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD). This state-of-the-art technology offers fast and precise quantification of liver stiffness and fat content, eliminating the need for invasive methods like biopsies. The process is swift, usually taking between 5 to 15 minutes, and simply involves positioning a probe on the skin above the liver. Sound waves are emitted from the probe to measure the stiffness of the liver tissue, aiding in the evaluation of fibrosis or scarring.
Who Are the Key Players in the Liver Disease Diagnostics Market?
Major companies operating in the liver disease diagnostics market are include:
• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• Fujifilm Holdings Corporation
• Echosens SA
• Boston Scientific Corporation
• Laboratory Corporation of America Holdings
• Quest Diagnostics Incorporated
• Siemens Healthineers AG
• bioMérieux SA
• Genentech Inc.
• Perspectum Diagnostics Ltd.
• Owlstone Medical Ltd.
• Enterome SA
• Atlentis Therapeutics AG
• 89bio Inc.
• Aligos Therapeutics Inc.
• BioPredictive SAS
• Cosara Diagnostics Pvt. Ltd.
• Hepion Pharmaceuticals Inc.
• HEPQuant LLC
• Aiforia Technologies Plc
What Is The Most Dominant Region In The Liver Disease Diagnostics Market?
North America was the largest region in the liver disease diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liver disease diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
